HomeCompareZIOP vs KMB

ZIOP vs KMB: Dividend Comparison 2026

ZIOP yields 231.03% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZIOP wins by $281.95M in total portfolio value
10 years
ZIOP
ZIOP
● Live price
231.03%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281.99M
Annual income
$152,307,756.02
Full ZIOP calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — ZIOP vs KMB

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZIOPKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZIOP + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZIOP pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP
Annual income on $10K today (after 15% tax)
$19,637.29/yr
After 10yr DRIP, annual income (after tax)
$129,461,592.62/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, ZIOP beats the other by $129,457,162.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + KMB for your $10,000?

ZIOP: 50%KMB: 50%
100% KMB50/50100% ZIOP
Portfolio after 10yr
$141.02M
Annual income
$76,156,483.67/yr
Blended yield
54.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ZIOP
No analyst data
Altman Z
-287.0
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys
0
KMB buys
0
No recent congressional trades found for ZIOP or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZIOPKMB
Forward yield231.03%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$281.99M$45.9K
Annual income after 10y$152,307,756.02$5,211.33
Total dividends collected$267.75M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ZIOP vs KMB ($10,000, DRIP)

YearZIOP PortfolioZIOP Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$33,803$23,102.69$11,314$613.68+$22.5KZIOP
2$109,153$72,984.41$12,865$759.19+$96.3KZIOP
3$337,052$220,258.08$14,709$943.96+$322.3KZIOP
4$996,281$635,635.69$16,919$1,180.17+$979.4KZIOP
5$2,821,960$1,755,939.31$19,588$1,484.33+$2.80MZIOP
6$7,667,803$4,648,304.92$22,838$1,879.06+$7.64MZIOP
7$20,008,593$11,804,044.41$26,832$2,395.60+$19.98MZIOP
8$50,195,948$28,786,753.46$31,788$3,077.63+$50.16MZIOP
9$121,203,020$67,493,355.30$38,000$3,986.82+$121.17MZIOP
10$281,994,987$152,307,756.02$45,872$5,211.33+$281.95MZIOP

ZIOP vs KMB: Complete Analysis 2026

ZIOPStock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ZIOP vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHDZIOP vs JEPIZIOP vs OZIOP vs KOZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.